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Maria Iqbal1,2,3,39, Reza Marooﬁan4,39, Büşranur Çavdarlı5,39, Florence Riccardi6,7,39, Michael Field8,39, Siddharth Banka9,10,
Dalal K. Bubshait11, Yun Li12, Jozef Hertecant13, Shahid Mahmood Baig3,14,15, David Dyment16, Stephanie Efthymiou4, Uzma Abdullah17,
Ehtisham Ul Haq Makhdoom1,2,3,18, Zafar Ali19, Tobias Scherf de Almeida12, Florence Molinari6, Cécile Mignon-Ravix6,
Brigitte Chabrol20, Jayne Antony21, Lesley Ades22,23, Alistair T. Pagnamenta24, Adam Jackson9,10, Soﬁa Douzgou9,10, Genomics England
Research Consortium*, Christian Beetz25, Vasiliki Karageorgou25, Barbara Vona26, Aboulfazl Rad26, Jamshaid Mahmood Baig27,
Tipu Sultan28, Javeria Raza Alvi28, Shazia Maqbool29, Fatima Rahman29, Mehran Beiraghi Toosi30, Farah Ashrafzadeh30,
Shima Imannezhad30, Ehsan Ghayoor Karimiani31,32, Yasra Sarwar3, Sheraz Khan3, Muhammad Jameel3, Angelika A. Noegel2,33,
Birgit Budde1, Janine Altmüller1, Susanne Motameny1, Wolfgang Höhne1, Henry Houlden4, Peter Nürnberg1,33, Bernd Wollnik12,34,
Laurent Villard6,7, Fowzan Sami Alkuraya35,36, Matthew Osmond16, Muhammad Sajid Hussain1,2,33 ✉ and Gökhan Yigit 12 ✉
PURPOSE: We aimed to deﬁne a novel autosomal recessive neurodevelopmental disorder, characterize its clinical features, and
identify the underlying genetic cause for this condition.
METHODS: We performed a detailed clinical characterization of 19 individuals from nine unrelated, consanguineous families with a
neurodevelopmental disorder. We used genome/exome sequencing approaches, linkage and cosegregation analyses to identify
disease-causing variants, and we performed three-dimensional molecular in silico analysis to predict causality of variants where
applicable.
RESULTS: In all affected individuals who presented with a neurodevelopmental syndrome with progressive microcephaly, seizures,
and intellectual disability we identiﬁed biallelic disease-causing variants in Protocadherin-gamma-C4 (PCDHGC4). Five variants were
predicted to induce premature protein truncation leading to a loss of PCDHGC4 function. The three detected missense variants
were located in extracellular cadherin (EC) domains EC5 and EC6 of PCDHGC4, and in silico analysis of the affected residues showed
that two of these substitutions were predicted to inﬂuence the Ca2+-binding afﬁnity, which is essential for multimerization of the
protein, whereas the third missense variant directly inﬂuenced the cis-dimerization interface of PCDHGC4.
CONCLUSION: We show that biallelic variants in PCDHGC4 are causing a novel autosomal recessive neurodevelopmental disorder
and link PCDHGC4 as a member of the clustered PCDH family to a Mendelian disorder in humans.
Genetics in Medicine; https://doi.org/10.1038/s41436-021-01260-4
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INTRODUCTION
Protocadherins (PCDHs) comprise a large family of over 80 cell
surface receptors that are mainly expressed during the
development of the vertebrate nervous system and play a
crucial role in the discrimination between self and nonself cell
surface identities in the course of establishment and generation
of neuronal circuits [1, 2]. Based on their genomic organization,
human PCDHs can be divided into two families which are either
encoded by genes distributed across the genome (nonclustered
PCDHs) or genes clustered in a 1-Mb region on human
chromosome 5 [3]. Clustered PCDHs (cPCDH) are encoded by
a total of 53 genes arranged in three subclusters (PCDHA,
PCDHB, and PCDHG) within this region [4–6]. All cPCDHs have a
similar structure. They are type I transmembrane proteins
containing six extracellular cadherin (EC) domains, a transmembrane region, and, in case of α- and γ-PCDH, an intracellular
domain (ICD) [1]. In the PCDHA and PCDHG subclusters,
multiple “variable” exons, that encode for the entire extracellular region, the transmembrane domain and a variable part
of the intracellular region, are tandemly arranged upstream of
three “constant” exons, which are shared within a subcluster
and code for a common C-terminal intracellular domain [4, 7].
cPCDHs are widely expressed in the developing and mature
nervous system including the spinal cord, cerebellum, and
hippocampus [8–11]. They have been shown to form homophilic cis- and trans-interactions inducing the formation of
multimeric protein complexes [12–14]. Neurons have been
suggested to create a unique “barcode” by the expression of
different combinations of these proteins that results in the
generation of neuron-speciﬁc sets of cis-dimers and allows
self–nonself discrimination based on the formation of transhomophilic interactions [2, 15]. Recent functional studies have
linked numerous cPCDHs to critical neuronal processes such as
regulation of neuronal survival, axon outgrowth and targeting,
dendrite arbor complexity, self-avoidance of sister axon and
dendrite branches, and synaptogenesis [8, 16–18]. Whereas
knockout mice of the α-Pcdh cluster are viable and fertile and
show only abnormal axonal projections of serotonergic and
olfactory sensory neurons [16, 19], disruption of the γ-Pcdh locus
leads to neonatal lethality [8, 20, 21]. Recent studies revealed
that Pcdhgc3, Pcdhgc4, and Pcdhgc5 are crucial for the observed
lethality [22, 23].
Hitherto, rare variants in nonclustered PCDH have been
identiﬁed in individuals with different neurodevelopmental
disorders. Rare biallelic variants in PCDH12 (OMIM 605622) and
PCDH15 (OMIM 605514) have been reported in patients with
diencephalic–mesencephalic junction dysplasia syndrome 1
(DMJDS1; OMIM 251280), Usher syndrome type 1F (USH1F,
OMIM 602083), and nonsyndromic hearing loss (DFNB23; OMIM
609533), respectively [24, 25]. Furthermore, more than 100
disease-causing variants have been described in PCDH19 (MIM
300460) in developmental and epileptic encephalopathy 9
(DEE9, OMIM 300088), making it one of the clinically relevant
genes in epilepsy [26]. So far, no disease-causing variant has yet
been identiﬁed in any of the cPCDHs to be causative for a
Mendelian disorder in humans, despite their important role
during neurodevelopment and in neural circuit assembly. In this
study, we report the identiﬁcation of biallelic disease-causing
variants in Protocadherin-gamma-C4 (PCDHGC4) in 19 individuals from nine unrelated families. Affected individuals presented with progressive microcephaly, global developmental
delay, intellectual disability, seizures, joint anomalies, and
additional dysmorphic features. These ﬁndings establish biallelic
PCDHGC4 variants as genetic cause for a novel neurodevelopmental disorder in humans, and elucidate the associated
phenotype.

MATERIALS AND METHODS
Subjects
Individuals who participated in this study were clinically characterized in
several clinics across the world (see Supplemental Information), and we
used the GeneMatcher tool [27] to connect centers in which genetic
analyses were performed. All individuals reported herein are born to
consanguineous families of different geographic origin, and respective
families were not related to each other. Subjects or their legal
representatives gave written informed consent for the molecular analyses,
publication of the results and clinical information, including photographs.
All studies were performed in accordance with the Declaration of Helsinki
protocols and were reviewed and approved by the local institutional ethics
board. DNA from participating family members was extracted from
peripheral blood lymphocytes by standard extraction procedures.

Genome/exome sequencing and linkage analysis
Genome and exome sequencing was performed on patient/parent trios
(family 8), single (family 9), or multiple affected family members (families
1–7). Details on sequencing and variant screening as well as genome-wide
linkage analysis (family 1) are provided as Supplementary Information.

Variant veriﬁcation and Sanger sequencing
Veriﬁcation of identiﬁed nonsense and missense variants was performed
using standard methods for polymerase chain reaction (PCR) ampliﬁcation
and Sanger sequencing. Primer sequences are available on request. The
coding sequence of PCDHGC4 (NM_018928.2) was analyzed and variants
were conﬁrmed by a second PCR on an independent DNA sample and
analyzed for cosegregation within the respective families.

Prediction programs
In silico prediction of the mutational effect for all missense variants was
performed using Combined Annotation Dependent Depletion (CADD;
https://cadd.gs.washington.edu), MutationTaster (www.mutationtaster.
org), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2), and SIFT
(https://sift.bii.a-star.edu.sg). Variants with potential effects on splicing
were characterized using ESEﬁnder and RESCUE ESE (see Supplemental
Information).

Structural analysis of mouse Pcdhgb7 and in silico analysis of the
mutational effect
Crystal structure of the Ca2+-bound form of mouse Pcdhgb7 was obtained
from the Protein Data Bank (www.wwpdb.org; PDB ID 5v5x). Structural
analysis, data visualization, and ﬁgure preparation were carried out with
the program PyMOL 2.3 (www.pymol.org; Schrödinger, LLC) and WebLab
viewerPro (Molecular Simulations Inc.).

RESULTS
Clinical presentation of individuals with a novel
neurodevelopmental phenotype
In a national and international collaboration, we recruited 19
individuals from nine unrelated families with a clinical diagnosis of
a neurodevelopmental disorder. Clinical ﬁndings on all affected
individuals are summarized in Table 1, with pedigrees and clinical
photographs shown in Fig. 1. Comprehensive clinical information
on families (1–4, 7, 8) is provided as Supplemental Information. For
ﬁve individuals (families 5, 6, and 9), no extensive clinical
descriptions are available.
Common features in our patient cohort were developmental
delay (DD)/intellectual disability (ID) (18/19), microcephaly (12/19),
seizures (10/19), hypotonia (10/19), and skeletal/joint anomalies
(10/19). Occipital–frontal circumferences (OFCs) at birth ranged
from 1.7 SD (individual IV-3, family 6) to −3 SD (individual VI-2,
family 5), and we observed microcephaly at birth (OFC ≤ −2 SD) in
2/19 patients. However, at follow up examinations, 12/19
individuals showed progressive mild to severe microcephaly with
values from −2 SD to −5.5 SD. Neuroimaging was available for 12
individuals. Brain magnetic resonance image/computed
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+

+

c.1449C>G; p.
(Asp483Glu)

Parental consanguinity

PCDHGC4 variant

3,000 (−0.4 SD)

NR

NR

Weight (g)

Height (cm)

Head
circumference (cm)

+

NR

–

–

–

Thin
cerebral cortex

–

Strabismus

Gait
abnormalities

Moderate

Speech
impairment,
started walking
at 4
years of age

Seizures

Brain MRI anomalies

Hearing impairment

Ocular anomalies

Additional ﬁndings

Intellectual disability

Development

Mild
Hyperactivity

Moderate
Hyperactivity

Kyphosis

–

–

Global developmental
delay, able to speak 2–3
words, able to toilet and
dress with assistance;
started walking
between 7 and 10 years

Severe

Hypotonic at birth,
unsteady gait,
hyperextensible joints

–

–

NR

–

NR

–

Severe
Global
developmental
delay, nonverbal,
uses signs and
gestures to
communicate;
walked at 10
years of age, able
to dress with
assistance

NR
Global
developmental
delay, no
language
development at
18 months,
deceased at
18 months

Moderate
Global
developmental
delay, walked at
the age of 2
years; able to
speak with a lot
of words and to
copy a text, able
to toilet and
to dress

Arthrogryposis

–

Severe

Hypotonic
at birth

NR

Cortical atrophy

+; generalized
seizures starting
at 18 months

+; status
epilepticus at
18 months
NR

Bilateral ulnar
clubhand, ﬂexion
contracture of
legs and
clubfoots

Long face, round
ears with
attached lobes,
thick lips with
everted inferior
lips, mild
prognathism

34 (−1 SD)

48 (−2 SD)

3,300 (−1 SD)

41

c.1817T>G; p.
(Val606Gly)

+

Morocco

Male

14

II-3

Bilateral ulnar
clubhand

NR

NR

NR

NR

NR

c.1817T>G; p.
(Val606Gly)

+

Morocco

Female

1 6/12b

II-2

Global
developmental
delay, able to
toilet and dress
with assistance;
started walking
between 7 and
10 years

Hypotonic at
birth, lumbar
scoliosis

–

–

Mild cortical
atrophy

+; generalized
seizures starting
at 5 years

Bilateral ulnar
clubhand, valgus
deformities

Long face, round
ears with
attached lobes,
thick lips with
everted inferior
lips, mild
prognathism

34 (−1 SD)

45 (−3 SD)

3,020 (−1 SD)

41

c.1817T>G; p.
(Val606Gly)

+

Morocco

Female

22

II-1

Severe

Hypotonic at
birth, unsteady
gait,
hyperextensible
joints;

–

–

NR

+; (singular)
febrile seizure

Swan neck
deformity

–

NR

Within
normal limits

Within
normal limits

40

c.1463C>T; p.
(Ala488Val)

+

Iraq

Female

24

II-3

Family 4

Global developmental
delay, nonverbal, able to
toilet and dress with
assistance; started
walking between 7 and
10 years

Hypotonic at birth,
unsteady gait,
hyperextensible joints,
white
hypopigmented patch

–

–

NR

–

–

+; at 1.5 and
6.5
years of age

Severe

Kyphoscoliosis

Cerebral
atrophy

+; at 2, 4 and 7
years of age

–

NR

Within normal limits

Within normal limits

40

c.1463C>T; p.(Ala488Val)

+

Iraq

Male

27

II-2

Broad thumbs, swan
neck deformity

–

NR

Within normal limits

Within normal limits

40

c.1463C>T; p.
(Ala488Val)

+

Iraq

Female

30

II-1

Family 3

Broad thumbs, swan
neck deformity

Hypoplasia
of toes

High narrow
palate, high
nasal bridge

35 (0.6 SD)

50 (0.2 SD)

3,500 (0.5 SD)

39

c.118C>T; p.
(Gln40*)

+

Turkey

Female

11

II-2

Aggressive
behavior, poor
self-care

Gait
abnormalities,
recurrent
infections

–
–

–

–

Acral anomalies

Clinodactyly,
hallux valgus

–
Sloping
forehead,
triangular
asymmetric
face, high nasal
bridge, high
narrow palate

34 (−0.5 SD)

45 (−2.4 SD)

3,850 (0.8 SD)

40

c.118C>T; p.
(Gln40*)

–

NR

NR

2,500 (−1.3 SD)

38

c.1449C>G; p.
(Asp483Glu)

+

Turkey

Female

20

Facial dysmorphism

Clinical characteristics

38

Gestation (weeks)

Birth

Pakistan

Pakistan

Geographic origin

Female

Male

Gender

8

10

Agea (years)

II-1

IV-3

V-1

Family 2

Family 1

Summary of genetic data and clinical features of affected individuals.

Pedigree ID

Table 1.
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IV-1

+

+

c.324del; p.
Phe108Leufs*14

Parental consanguinity

PCDHGC4 variant

+; tonic seizures
starting at
18 months, last
seizure at 8 3/
12 years

Broad thumbs

Acral anomalies

Seizures

Mild metopic
craniosynostosis,
everted
inferior lips

Facial dysmorphism

Clinical characteristics

53 (0.8 SD)

45 (−3 SD)

32 (−3 SD)

Height (cm)

Head
circumference (cm)

–

–

–

+; neonatal,
tonic seizures

Epicanthic fold, high
nasal bridge, low set
ears,
overlapping teeth

NR

NR

3,600 (0.4 SD)

At term

c.1463C>T; p.
(Ala488Val)

+

Saudi Arabia

Female

NR

149

49

II-2

Mild metopic
craniosynostosis

35.5 (0.2 SD)

3,700 (0.2 SD)

40

2,460 (−3 SD)

Weight (g)

41

c.324del; p.
Phe108Leufs*14

Gestation (weeks)

Birth

Iran

Iran

Geographic origin

1 6/12

Gender

Female

8 5/12

Female

Agea (years)

VI-2

NR

3

Family 6

Family 5

VI-1

Pedigree ID

NR

153

NR

Weight (kg)

113 (−2.5 SD)

127 (−2 SD)

Height (cm)

53

45 (−4.7 SD)

45 (−4.5 SD)

Family 2
II-1

V-1

Family 1

IV-3

Head
circumference (cm)

Current measurements

Pedigree ID

39

150 (−2.1 SD)

51 (−2.5 SD)

–

–

Epicanthic fold, high
nasal bridge, low set
ears,
overlapping teeth

37 (1.7 SD)

51 (0.3 SD)

3,900 (1.1 SD)

39

c.1463C>T; p.
(Ala488Val)

+

Saudi Arabia

Male

1

IV-3

Family 3
II-1

Family 7

–

Persistent fetal
ﬁngertip pads, mild
2nd and 5th
clinodactyly

Doliocephaly, mild
synophrys,
upslanting
palpebral ﬁssures,
long eyelashes,
high nasal bridge,
hooked nose,
overhanging
columella, short
philtrum, full lips,
high narrow palate,
mild malar
hypoplasia

34 (−1.5 SD)

52 (−0.4 SD)

3,645 (−0.7 SD)

42

c.1243C>T; p.
(Arg415*)

+

Lebanon

Male

17

III-1

38.5

164 (−1.8 SD)

51 (−3.7 SD)

II-2

–

Mild 2nd and 5th
ﬁnger clinodactyly,
small broad feet

Mild synophrys, long
eyelashes, high nasal
bridge, broad nasal
bridge and nasal tip,
slightly overhanging
columella, short
philtrum, full lips

35 (0.3 SD)

51 (0.3 SD)

3,325 (−0.1 SD)

39

c.1243C>T; p.(Arg415*)

+

Lebanon

Male

6

III-4

32.4

48

152 (−2 SD)

52 (−2 SD)

II-1

Family 4

+; febrile seizures

–

–

–

Microcephaly,
receding forehead

32.4 (−1.7 SD)

NR

2,330 (−2.5 SD)

40

c.1724dup; p.
(Leu575Phefs*63)

+

Sudan

Female

11

IV-1

Family 8

NR

NR

NR

II-2

Mild synophrys, long
eyelashes, high nasal
bridge, short
philtrum, full lips

35 (0.3 SD)

49 (−0.1 SD)

3,280 (0.3 SD)

38

c.1243C>T; p.
(Arg415*)

+

Lebanon

Male

2

III-5

150 (−2.1 SD)

49 (−3.9 SD)

II-3

–

Bilateral thumbin-palm
deformity, rigid
equinovarus
deformity (right
foot), ﬁxed rocker
bottom deformity
with severe
calcaneovalgus
(left foot)

Mildly
dysmorphic chin,
low nasal bridge,
small, upturned
nose, long
philtrum,
metopic
craniosynostosis

NA

NA

NA

At term

c.2443-1G>Ac

+

Jordan

Male

1 10/12

IV-1

Family 9

38

138 (−2 SD)

51 (−2 SD)

II-3

4
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Severe

Global
developmental
delay, started
walking at the age
of 4 years, only
babbling

Intellectual disability

Development

48 (−3.6 SD)

127 (−0.5 SD)

35 (0.8 SD)

Head
circumference (cm)

Height (cm)

Weight (kg)

Current measurements

DDH

9 (−1.0 SD)

67 (−4.7 SD)
28 (−3.4 SD)

81 (−2.5 SD)

44 (−2.5 SD)

7.3 (−0.6 SD)

63.5 (−2.1 SD)

41 (−2.5 SD)

72

155.5 (−2.9 SD)

56.5 (0.3 SD)

–
Global
developmental delay

–
Global
developmental delay,
severe receptive and
expressive
language delay

Moderate
Global
developmental
delay, can stand
with support

43 (−2.4 SD)

Moderate
Severe speech
delay and
articulation
problems,
moderate
intellectual
disability

Spasticity and truncal
hypotonia, hip
dislocation (left)

Neonatal
hypertonia, 15o
contractures at
elbows, hypoplastic
calves, mild genu
valgum, brisk
reﬂexes

Oculomotor apraxia

–

Spasticity and truncal
hypotonia,
bilateral DDH

DDH

Esotropia

Additional ﬁndings

–

Esotropia

Ocular anomalies

–

–

Microphthalmus,
ptosis of the
right eye

Hearing impairment
Exotropia, mild
oculomotor
apraxia

21

126 (+0.4 SD)

51 (−0.9 SD)

13

95 (−1.3 SD)

47 (−1.2 SD)

Mild
Severe speech delay,
global
developmental delay

Moderate

Neonatal hypertonia,
exaggerated startle
response

Oculomotor apraxia

–

Absent speech, global
developmental delay

Neonatal hypertonia,
exaggerated startle
response

Oculomotor apraxia

–

15.1 (−2.90 SD)

104 (−2.87 SD)

46.5 (−3.72 SD)

NA

NA

NA

Mild
Global
developmental
delay, no smiling,
reduced social
interaction

Moderate

Arthrogryposis
multiplex
congenital
(shoulders
elbows, hips,
and knees)

Oculomotor
apraxia, restricted
ocular motility,
bilateral ptosis,
axial myopia of
the right eye,
myopic
astigmatism of
the left eye

–

NR

IV-1

Family 9

Walking at age 5 years
4 months, speech
delay, single words at
age 10 years,
understands simple
conversations and
commands in English
and Arabic

Arthrogryposis
multiplex congenita
(mainly elbows and
ankles), slow weight
gain, vitamin D
deﬁciency

Oculomotor apraxia

–

Frontal horns mildly
prominent with mild
atrophy (at 7 years)

NR

Mild ventriculomegaly
and thinning of
anterior body of
corpus callosum

Left temporal fossa
arachnoid cyst, mild
ventriculomegaly
and thinning of
body and genu of
corpus callosum

Acute ischemic insult
within the left
thalamus and left
parietal region

–

Left-sided
hypodensities within
the temporal lobe
and left cerebral
hemisphere as results
of previous
microhemorrhages;
CSF space
enlargement
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III-4

Family 8

III-1

Family 7
IV-3

Mild extra axial
widening

IV-1

VI-2

VI-1

Mild extra axial
widening (at 4 6/
12 years of age)

Family 6

Family 5

Brain MRI anomalies

Pedigree ID
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Fig. 1 Pedigrees and clinical characteristics of individuals harboring biallelic disease-causing variants in PCDHGC4. (a) Pedigrees of nine
unrelated families with disease-causing variants in PCDHGC4. All affected siblings (solid symbols) in each family carry homozygous diseasecausing variants in PCDHGC4 while unaffected parents are heterozygous for identiﬁed PCDHGC4 variants (white symbols). (b) Upper panel:
facial features of subjects IV-3 and V-1 from family 1 (left), clinical characteristics of subjects II-1 and II-2 from family 2 showing kyphoscoliosis,
clinodactyly and hallux valgus (subject II-1), and kyphosis and hypoplasia of the toes (subject II-2). Lower panel (from left to right): facial
features and hand anomalies observed in subjects II-1 (22 years) and II-3 (14 years) from family 4, clinical characteristics of subjects VI-1 and VI2 from family 5, and subjects IV-2 and IV-3 from family 6, and facial features and feet anomalies observed subject VI-1 from family 8.
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Fig. 2 Neuroradiologic features of affected individuals. Sagittal (a) and axial (b) T2-weighted images of subject IV-3 from family 1 at the age
of 10 revealed no structural brain anomalies but showed microcephaly and thin cerebral cortex. (c) Sagittal T1 section after gadolinium
injection of subject II-1 (family 4) at 10 years of age and (d) axial T2-weighted images at 16 years revealed no brain-speciﬁc abnormality except
for a discreet prominent aspect of the lateral ventricles. (e) Sagittal T1 section after gadolinium injection and (f) axial T2-weighted images of
subject II-3 (family 4) at 7 years of age revealed a prominent aspect of the lateral ventricles, of the 3rd and, to a milder degree, of the 4th
ventricle. (g) Coronal T2-weighted and (h) axial T2-Flair images of subject IV-2 (family 6) at 3 months of age showing normal signal intensity,
age-appropriate myelination process and slightly enlarged cerebrospinal ﬂuid (CSF). Coronal (i) and sagittal (j) computed tomography (CT)
images of the same subject at the age of 3 years revealing left-sided subcortical hypodensity within left temporal lobe and conﬁrming
prominent CSF space.

tomography (MRI/CT) abnormalities (11/12 patients) were rather
nonspeciﬁc (Fig. 2, Table 1). Microcephaly, thin cerebral cortex,
mild ventriculomegaly, and cortical atrophy were the commonest
features. Seizure types ranged from singular febrile seizures
(family 3, subject II-3), recurring events (family 2, subjects II-1 and
II-2) to generalized tonic, clonic–focal to multifocal seizures
(families 4 and 5; Table 1). Electroencephalogram (EEG) data was
available for four subjects (family 2, subjects II-1 and II-2; family 5,
subject VI-2; family 7, subjects III-1) and showed no abnormalities.
ID and DD were present in all our patients, and we observed
motor and speech developmental delay as well as mild to severe
cognitive impairment. Three individuals presented with kyphosis
and/or scoliosis, hyperextensible joints were observed in three
individuals and contractures as wells as arthrogryposis were
present in four individuals (Fig. 1b, Table 1). Dysmorphic facial
features were rather nonspeciﬁc and did not reveal a common,
recognizable facial presentation within our patient cohort (Fig. 1b,
Table 1).
Identiﬁcation of biallelic truncating and missense PCDHGC4
variants
We performed linkage analysis (family 1) and/or genome/exome
sequencing in probands and proband/parent trios. Based on
parental consanguinity, autosomal recessive inheritance was
considered likely, and we prioritized homozygous, rare exonic,
and splice site variants (see Supplemental Information). We
identiﬁed three different missense variants and ﬁve protein
truncating variants in the Protocadherin-gamma family member
PCDHGC4 (OMIM 606305; NM_018928.2) in all affected individuals (Fig. 3a, b, S1, Table 2). All variants fully cosegregated with
the phenotype in the respective families and are absent or very
rare in the general human population with minor allele
frequencies (MAFs) ranging from 0 to 4*10−6, in line with an
autosomal recessive pattern of inheritance (Table 2). We
identiﬁed four homozygous loss-of-function variants in
PCDHGC4, c.118C>T (p.[Gln40*]), c.324del (p.[Phe108Leufs*14]),
c.1243C>T (p.[Arg415*]), c.1724dup (p.[Leu575Phefs*63]), that
were predicted to lead to an early stop and premature protein
truncation, and were absent from the gnomAD database
(Fig. 3b, Table 2). In family 9, we found the homozygous variant
c.2443-1G>A at the acceptor splice site of intron 1, and by
Genetics in Medicine

employing an exon‐trapping approach we could show that this
variant leads to a loss of the acceptor splice‐site recognition
resulting in severe splicing defects such as whole‐exon skipping
or usage of a cryptic exonic acceptor splice site, which both are
predicted to induce a frameshift and premature protein
truncation (Fig. 3b, S3). Within the family of γ-PCDHs, PCDHGC4
is the only member that is not only highly conserved across
species, but also under strict mutational constraint [23].
Truncating variants in PCDHGC4 are rarely observed in healthy
control individuals. For the canonical transcript of PCDHGC4
(ENST00000306593.1, NM_018928.2) only 12 alleles with nonsense variants, all in heterozygous state, were reported in the
gnomAD database in contrast to 29.6 that were expected to be
observed in the >240,000 alleles (probability of loss of function
intolerance [pLI] = 0.98). Further, biallelic copy-number variants
(CNVs) encompassing PCDGHC4 have not been reported so far
in the DECIPHER database, the Database of Genomic Variants
(DGV), and the structural variant (SV) data set of gnomAD with
only two (DGV) and six (gnomAD) heterozygous alterations
enlisted in these data sets that affect PCDHGC4. Interestingly,
genetic disruption of the entire γ-Pcdh cluster as well as
singular knockout of Pcdhgc4 in mice also cause a severe
neurodevelopmental phenotype, both resulting in neurodegeneration in late embryonic stages and leading to early neonatal
lethality [8, 20–23].
Furthermore, we identiﬁed three different homozygous missense variants, c.1449C>G (p.[Asp483Glu]), c.1463C>T (p.[Ala488Val]), and c.1817T>G (p.[Val606Gly]), in PCDHGC4 in affected
individuals of four additional consanguineous families (Fig. 3,
Table 2). In silico prediction of the pathogenic effect of these
missense variants by different prediction tools leads to the
classiﬁcation as damaging (SIFT), probably damaging (PolyPhen2), and a Combined Annotation Dependent Depletion (CADD)
score of 24.1 to 26.9, indicating deleteriousness of these variants
(Table 2). Two missense variants, p.(Asp483Glu) and p.(Ala488Val),
were classiﬁed as polymorphisms by a single in silico prediction
tool, MutationTaster. In two families, families 3 and 6 from Iraq
and Saudi Arabia, respectively, we identiﬁed the identical
missense variant, c.1463C>T (p.[Ala488Val]), in PCDHGC4. In
affected individuals of both families, this variant was within a
shared haplotype of approximately 309 kb between
chr5:140,750,044 and chr5:141,059,868 suggesting a founder
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Fig. 3 Molecular characterization and in silico analysis of identiﬁed disease-causing variants in PCDHGC4. (a) Schematic representation of
the human γ-PCDH cluster. Variable exons of the γ-PCDH A and B subfamilies are shown in gray and black, respectively. Variable exons of the γPCDH C subfamily are shown in purple, γ-PCDH constant exons in blue. (b) Schematic representation of the genomic (upper panel) and protein
structure (lower panel) of PCDHGC4, and localization of the identiﬁed disease-causing variants. Introns are shown by black horizontal line,
coding exons by purple and blue bars, noncoding regions of exons by small blue bar (upper panel). Scale bar is referring solely to exons.
Protein structure of PCDHGC4 with six extracellular cadherin (EC) repeats (purple), the transmembrane region (gray), and the intracellular
domain (ICD, blue). (c) Amino acid sequence alignment of PCDHGC4 across different species including mouse Pcdhgb7 (lower line, all panels)
for residues p.Asp483 and p.Ala488 (upper panel) and p.Val606 (lower panel) that are altered in the affected subjects. Protein sequences were
prepared from UniProtKB and alignment was performed using Clustal Omega. Position of the altered residues in human are indicated (top
numbers). (d) Three-dimensional structure of the EC3 to EC6 domains of Pcdhgb7. Structural information was obtained from the Protein Data
Bank (PDB) and is available under the accession number 5v5x. Pcdhgb7 is shown in ribbon representation. β-strands are shown as arrows
(blue), a short helical part in red, calcium ions in sphere representation (green), and aspartate at position 478 within the Ca2+-binding DXD
motif in space ﬁlling representation (red). (e-g) Close up crossed eyes stereo views of p.Asp478 in Pcdhgb7 corresponding to p.Asp483 in
PCDHGC4 (e), p.Gly483 (corresponding to p.Ala488 in PCDHGC4) (f), and p.Leu602 (corresponding to p.Val606 in PCDHGC4) (g). Affected
amino acid residues are labeled in red, calcium ions are shown in sphere representation (light green), oxygen ligands of the adjacent calcium
ion in space ﬁlling representation (f, dark green), surrounding hydrophobic residues p.Pro558, p.Tyr604, and p.Val644 of p.Leu602 in space
ﬁlling representation in yellow (g).

nature of the variant. On protein level, the three missense variants
are located in the extracellular domain of PCDHGC4 within the
ﬁfth (p.[Asp483Glu) and p.(Ala488Val]) or sixth (p.[Val606Gly])
extracellular cadherin (EC) domain and are predicted to lead to the
substitution of phylogenetically highly conserved amino acids in
PCDHGC4 (Fig. 3c). EC domains are extracellular Ca2+-binding
domains, which upon Ca2+ binding can mediate conformational
changes inﬂuencing the rigidity of the EC domains of PCDHGC4,
which enables cis- and trans-homophilic interactions [2]. Ca2+
binding is a crucial process for correct PCDH function. Upon
binding of Ca2+, which is mediated by several calcium-binding
motifs at the junctions of the EC repeats of PCDHs, the
conformation and rigidity of these segments is controlled,

allowing formation of cis- as well as trans-dimerizations [28, 29].
Whereas EC1 to EC4 contribute to the formation of head-to-tail
trans interactions between different cells, EC5 and EC6 are
involved in cis-dimerization processes. To gain further insights
into the pathogenic effects of the missense variants, we
performed an in silico analysis of the mutational effect on the
protein structure using the crystal structure of mouse Pcdhgb7, a
close homologue of PCDHGC4. All three missense variants were
located in or directly adjacent to a Ca2+-binding motif. The p.
(Asp483Glu) variant affects an aspartate that is part of the highly
conserved DXD motif in the EC5 repeat of PCDHGC4 directly
involved in calcium coordination (Fig. 3d, e). Although this variant
does not change the charge of the coordinating residue, it alters
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cDNA complementary DNA, D deleterious, DC disease causing, NA not applicable, PD probably damaging.
a
Accessed in January 2021.
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HumVar prediction, score 0–1.
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Table 2.

In silico prediction and population allele frequencies of PCDHGC4 (NM_018928.2; ENST00000306593.1) variants identiﬁed in this study.

MutationTasterd

CADD

9
the size of the residue, which is predicted to perturb the local
structure and to shift the position of the coordinating carboxyl
oxygens of this residue away from the optimal geometry of
calcium-binding ligands. This should decrease the Ca2+-afﬁnity of
this motif. Interestingly, a similar substitution, p.Asp377Glu, has
already been described for PCDH19, and it has been shown to
impair PCDH19 function and cause early infantile epileptic
encephalopathy [30]. The p.(Ala488Val) alteration is located in
close proximity to the DXD motif within the ﬁfth EC repeat (Fig. 3d,
f). Structural analysis of this highly conserved residue shows that
the +5 position (in relation to the DXD motif) is generally a small
amino acid (glycine or alanine). Substitution of this residue with
valine, as identiﬁed in our patients, introduces a large, hydrophobic amino acid, which might interfere with the adjacent Ca2
+
-binding motif, thereby impairing Ca2+-afﬁnity of PCDHGC4
(Fig. 3f). Similarly, also the p.Val606 is located in proximity to a
DXD motif of PCDHGC4. In contrast to the other missense variants,
the p.(Val606Gly) substitution is located in the third strand of a
seven-stranded β-sheet of the sixth EC domain, embedded in a
hydrophobic pocket (Fig. 3g). Substitution of valine at position 606
with glycine is predicted to cause structural perturbation of this
region, which potentially might impair these interactions and, as a
result, directly affect the cis-dimerization capability of PCDHGC4.
Cis-dimerization of γ-PCDH is not only important for trans
homophilic interactions on the cell surface, but also essential for
cell surface delivery of newly synthesized γ-PCDH itself, as
demonstrated by experiments on induced mutational disruption
of the cis-interface [31]. Currently, we can only speculate about the
direct effect of these three identiﬁed missense variants on
PCDHGC4 protein function, but given the fact that they are all
located in the ﬁfth or sixth EC repeat, it seems likely that they
directly or indirectly inﬂuence these cis-dimerization processes,
thereby interfering with cell surface transport of PCDHGC4containing dimers [31].
In an additional family from Iran, we identiﬁed the homozygous
missense variant c.2524G>C (p.[Gly842Ser]) in a patient presenting
with facial dysmorphism, metopic craniosynostosis, ventriculomegaly, focal clonic seizures, and moderate global developmental
delay (Fig. S4). This variant affects a residue within the ICD of
PCDHGC4. The ICD of γ-PCDH plays an important role in the
regulation of downstream signaling cascades, e.g., in the
inhibition of FAK and PYK2 kinase activity, which is crucial for
the promotion of dendrite arborization in cortical neurons [17].
Still, further studies are required to prove causality of this variant
as well as to fully determine the speciﬁc function and involvement
of this residue in intracellular, γ-PCDH-regulated signaling
pathways.
DISCUSSION
In the present study, we provide strong genetic evidence that
biallelic nonsense and missense variants in PCDHGC4 cause a
distinct neurodevelopmental phenotype comprising progressive
microcephaly, short stature, intellectual disability, seizures, and
joint anomalies. In all 19 affected individuals from nine different
families, we were able to identify homozygous disease-causing
variants in PCDHGC4 that most likely lead to a loss of function of
the encoded protein.
Interestingly, we observed seizures in 10 of 19 patients.
Generally, development of focal seizures is considered to be
caused by a disturbance of the excitation/inhibition balance in
cortical neurons. Within these neuronal circuits, GABAergic
cortical inhibitory interneurons (cINs) play an important role in
restraining excitation levels in the brain under normal conditions, and alterations in the number of cINs have been
associated with epilepsy [32]. During embryonic development,
the number of cINs is regulated by programmed cell death.
Initially, excess numbers of cINs are generated from a pool of cIN
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progenitor cells which migrate to the developing cortex. Upon
arrival, ~40% of these cells are eliminated by endogenously
triggered programmed cell death [33–35]. Interestingly, except
Pcdhga9, all 21 γ-Pcdhs are expressed in cINs. Expression of four
isoforms, Pcdhga1, Pcdhga2, Pcdhgc4, and Pcdhgc5, increases
signiﬁcantly between P8 and P15, corresponding to the period
in which programmed cell death of cINs takes place [36]. Recent
studies showed that Pcdhgc3, Pcdhgc4, and Pcdhgc5 are crucial
components in the regulation of this programmed cell death.
Loss of these isoforms enhances the number of cINs undergoing
apoptosis, which results in a reduced cortical density of cINs
[36]. A similar function of γ-PCDHs in controlling programmed
cell death has also been described for neuronal cells of the
spinal cord and the retina [8, 9, 22]. Still, further molecular and
cellular studies are required to determine whether diseasecausing variants in PCDHGC4 alone are sufﬁcient to increase
programmed cell death in neuronal cells and to give rise to the
clinical presentation observed in our patients via this pathway.
Interestingly, genetic disruption of the entire γ-Pcdh cluster as
well as singular knockout of Pcdhgc4 in mice both result not only
in neurodegeneration in late embryonic stages but also lead to
early neonatal lethality [8, 20–23]. Currently, it is unclear why
disruption of Pcdhgc4 in mice leads to neonatal lethality,
whereas biallelic loss-of-function variants in human, as observed
in our patients, result in a milder neurodevelopmental disorder
comprising progressive microcephaly, seizures, and intellectual
disability, especially when considering that both humans and
mice share the same set of 22 members within the γ-PCDH
cluster. But the difference between the observed phenotypes
suggests that the human brain might compensate for the
functional failure of PCDHGC4 resulting in a higher tolerance of
loss-of-function variants in terms of lethality.
So far, to the best of our knowledge, no member of the
clustered PCDH family has been shown to be involved in the
pathogenesis of a congenital human disorder. In recent years,
disease-causing variants in several nonclustered δ-PCDH family
members have been described and closely linked to different
neurodevelopmental diseases. This includes biallelic loss-offunction variants in PCDH12 and PCDH15, which were identiﬁed
as cause of diencephalic–mesencephalic junction dysplasia
syndrome type 1 (DMJDS1), Usher syndrome type 1F, and
nonsyndromic hearing loss, respectively, as well as PCDH19, in
which over 100 different missense and nonsense variants have
been reported to underlie X-linked developmental and epileptic
encephalopathies 9 (DEE9) highlighting the importance of
cell–cell communication via PCDH19 at the early stages of brain
development [24–26, 37]. Although recent studies indicate that
complete or partial epigenetic dysregulation of the clustered
PCDH occurs in cells of patients with Williams–Beuren syndrome
or Down syndrome, and hypermethylation of all three PCDH
clusters is detectable in Wilms tumors, a direct link to a
monogenic, congenital human disorder has not been established
before [38–40]. Currently, it is unclear whether this is due to
functional redundancy of the encoded PCDHs. Mice lacking the αor β-Pcdh cluster are viable and fertile [16], whereas knockout of
the whole γ-Pcdh cluster results in neonatal lethality [8, 20, 21].
Similar consequences were observed when only the γC3 to γC5
isoforms within this cluster were disrupted, indicating that one of
these three isoforms has a critical function [22]. Very recent results
based on the generation of single knockouts of γ-Pcdh members
suggest that Pcdhgc4 is the crucial isoform within the gamma
cluster, which is required for neuronal survival and responsible for
neonatal lethality [23]. The unique role of PCDHGC4 is further
supported by genetic data indicating that PCDHGC4 is the only
member within the γ-PCDH cluster that is under strict mutational
constraint [23]. We can only speculate about the molecular basis
of the distinct role of PCDHGC4, especially as its overall structure is
similar to other γ-PCDHs.

In conclusion, we show that biallelic truncating and missense
variants in PCDHGC4 cause a speciﬁc human phenotype characterized by neurodevelopmental delay, progressive microcephaly with
mild to severe intellectual disability, global developmental delay,
joint anomalies, and seizures, providing evidence that diseasecausing variants in a single member of the clustered PCDH family
are involved in the pathogenesis of a congenital disorder in humans.
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